Compare Cytokinetics Inc (CYTK) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Boston Beer Company Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Boston Beer Company Inc trades at $168.61 (market cap $1.76B). The key difference: Cytokinetics Inc is far larger — about 6.3× Boston Beer Company Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | SAM | |
|---|---|---|
Market Cap | $11.12B | $1.76B |
Sector | Technology | Consumer Staples |
52-Week High | $87.26 | $260.05 |
52-Week Low | $33.23 | $161.08 |
Enterprise Value | $11.59B | $1.63B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Boston Beer Company (SAM) trades at $172.39, down 2.49% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, but faces headwinds with negative 2026 profit margin projections. Recent news highlights innovation in Beyond Beer products and marketing initiatives, though Q1 2026 earnings missed expectations and volume growth concerns persist.
The stock presents a cautious opportunity with analyst consensus target of $213.50 offering 24% upside, but investors face risks from declining volumes, margin pressure, and competitive threats. While cash flow remains positive and valuation ratios appear reasonable, the negative 2026 earnings outlook and bearish technical momentum warrant careful monitoring of upcoming Q2 results and brand performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
